公开(公告)号：US20240409653A1

公开(公告)日：2024-12-12

申请号：US18698354

申请日：2022-10-05

Applicant: GENMAB A/S ,  BIONTECH SE ,  MSD INTERNATIONAL BUSINESS GMBH

Inventor： Alexander MUIK ,  Kristina NÜRMBERGER ,  Nora PENCHEVA ,  Maria N. JURE-KUNKEL ,  Ugur SAHIN

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present disclosure relates to combination therapy using a binding agent that binds to human PD-L1 and to human CD 13 7 in combination with pembrolizumab to reduce or prevent progression of a tumor or treating cancer.

公开(公告)号：US20240400703A1

公开(公告)日：2024-12-05

申请号：US18660847

申请日：2024-05-10

Applicant: Genmab A/S ,  BioNTech SE

Inventor： Kristel Kemper ,  Maarten van der Kroef ,  Dennis Verzijl ,  Andrea Gorlani ,  Pauline Linda de Goeje ,  Lars Guelen ,  David Satijn ,  Esther C. W. Breij ,  Ugur Sahin ,  Sina Fellermeier-Kopf ,  Maren Köhne

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US12150947B2

公开(公告)日：2024-11-26

申请号：US16957898

申请日：2019-01-10

Applicant: BioNTech SE ,  TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GGMBH

Inventor： Ugur Sahin ,  Heinrich Haas ,  Annette Vogel ,  Stephanie Erbar ,  Kerstin Walzer ,  Anne Schlegel ,  Sebastian Hörner ,  Jorge Herrero Moreno ,  Thorsten Klamp ,  Sebastian Kreiter ,  Mustafa Diken ,  Phillip Heller

IPC: A61K31/70 ,  A61K9/00 ,  A61K35/763 ,  A61K47/18

Abstract: The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine.

公开(公告)号：US20240366754A1

公开(公告)日：2024-11-07

申请号：US18701119

申请日：2022-10-14

Applicant: BioNTech SE

Inventor： Richard B. Gaynor ,  Michael Steven Rooney ,  Asaf Poran ,  Theresa Addona ,  Scott Goulding ,  Ekaterina Esaulova ,  Miles Kirsch ,  Yunpeng Liu ,  Lauren Stopfer

IPC: A61K39/25 ,  A61K39/00 ,  A61K39/12 ,  A61K39/245 ,  A61P37/04 ,  C07K14/005

Abstract: The present disclosure provides pharmaceutical compositions for delivery of viral antigens (e.g., a viral vaccine) and related technologies (e.g., components thereof and/or methods relating thereto).

公开(公告)号：US20240335511A1

公开(公告)日：2024-10-10

申请号：US18268124

申请日：2021-12-20

Applicant: BioNTech SE

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Lena Mareen KRANZ ,  Mathias VORMEHR ,  Sina FELLERMEIER-KOPF ,  Jan DIEKMANN ,  David EISEL

IPC: A61K38/20 ,  A61K9/51 ,  A61K38/38 ,  A61K48/00 ,  A61P35/00 ,  C07K14/54 ,  C07K14/55 ,  C07K14/765

CPC classification number: A61K38/2046 ,  A61K9/5146 ,  A61K38/2013 ,  A61K38/38 ,  A61K48/0041 ,  A61P35/00 ,  C07K14/5418 ,  C07K14/55 ,  C07K14/765 ,  C07K2319/31

Abstract: This disclosure relates to the field of therapeutic RNA to treat cancer, in particular advanced solid tumors such as metastatic (Stage IV) or unresectable localized cancer. Disclosed herein are compositions, uses, and methods for treatment of cancers. Administration of therapeutic RNAs to a patient having cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.

公开(公告)号：US12054723B2

公开(公告)日：2024-08-06

申请号：US16898176

申请日：2020-06-10

Applicant: BioNTech SE ,  TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg—Universität Mainz gG

Inventor： Florian Eberle ,  Ugur Sahin ,  Andreas Kuhn ,  Britta Vallazza ,  Mustafa Diken

IPC: C12N5/00 ,  A61K39/00 ,  A61K48/00 ,  C12N15/67 ,  C12N15/68 ,  C12N15/70 ,  C12N15/85 ,  C12P19/34 ,  C12P21/00

CPC classification number: C12N15/68 ,  A61K39/00 ,  A61K48/0066 ,  C12N15/67 ,  C12N15/70 ,  C12N15/85 ,  C12P19/34 ,  C12P21/00 ,  A61K2039/53 ,  C12N2830/50

Abstract: The present invention relates to nucleic acid molecules containing poly (dA:dT) regions which are stabilized in E.-coli, methods of propagating such nucleic acid molecules in E. coli, methods of obtaining RNA, peptides or proteins using such nucleic acid molecules and to RNA which is obtained from such nucleic acid molecules and its use. In particular, the poly (dA:dT) regions contain at least one disruption by a sequence not encoding a sequence solely composed of A residues.

公开(公告)号：US20240043527A1

公开(公告)日：2024-02-08

申请号：US17915567

申请日：2021-03-29

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Claudia Lindemann ,  Jan Diekmann ,  Kerstin Brettschneider ,  Hayat Bähr-Mahmud ,  Ursula Ellinghaus ,  Leyla Fischer ,  Christiane Stadler ,  Özlem Türeci

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/28 ,  A61P35/00 ,  C07K2317/522 ,  C07K2317/14

Abstract: The present disclosure provides RNA technologies for targeting Claudin-18.2 polypeptides. In some embodiments, such RNA technologies can be useful for treatment of diseases associated with positive expression of Claudin-18.2. For example, in some embodiments, such RNA technologies can be useful for treatment of Claudin-18.2 positive cancer, including, e.g, but not limited to biliary cancers, ovarian cancers, gastric cancers, gastro-esophageal cancers, pancreatic cancers. In some embodiments, such RNA technologies can be used in combination therapy (e.g, in combination with a chemotherapeutic agent).

公开(公告)号：US20240000921A1

公开(公告)日：2024-01-04

申请号：US18341590

申请日：2023-06-26

Applicant: BioNTech SE

Inventor： Alexander Muik ,  Asaf Poran ,  Kena Anne Swanson ,  Qi Yang ,  Hui Cai ,  Ugur Sahin ,  Kayvon Modjarrad

IPC: A61K39/215 ,  C07K14/005

CPC classification number: A61K39/215 ,  A61K2039/53 ,  C07K14/005

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses.

公开(公告)号：US20230265454A1

公开(公告)日：2023-08-24

申请号：US18007550

申请日：2021-06-01

Applicant: BioNTech SE ,  TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenber-Universitä Mainz

Inventor： Mario Perkovic ,  Sonja Witzel ,  Tim Beissert ,  Ugur Sahin

IPC: C12N15/86 ,  C12N15/113

CPC classification number: C12N15/86 ,  C12N15/113 ,  C12N2770/36143

Abstract: The present invention embraces an RNA replicon (self-amplifying RNA vector (saRNA)) that can be replicated by a replicase of a self-replicating virus, e.g., a replicase of alphavirus origin. According to the invention, translation of the replicase open reading frame is uncoupled from a 5′-terminal cap by placing translation of the replicase open reading frame under the translational control of an internal ribosome entry site (IRES). Thereby the initiation of translation depends on the molecular properties of the respective IRES, which compared to cap-dependent translation may require less or no cellular initiation factors to direct the ribosome to the translational start site. According to the invention, IRES-controlled replicase translation may allow the use of uncapped synthetic saRNA. Furthermore, the use of an IRES provides for the option to insert additional transgenes upstream to the IRES.

公开(公告)号：US11701413B2

公开(公告)日：2023-07-18

申请号：US16500005

申请日：2018-04-10

Applicant: BioNTech SE ,  TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH

Inventor： Ugur Sahin ,  Sebastian Kreiter ,  Christina Krienke ,  Jutta Petschenka ,  Lena Mareen Kranz ,  Mustafa Diken

IPC: A61K39/00 ,  A61P37/06 ,  C12N15/11 ,  C12N15/117

CPC classification number: A61K39/0008 ,  A61P37/06 ,  C12N15/11 ,  C12N15/117 ,  A61K2039/53 ,  A61K2039/55555 ,  C12N2310/335

Abstract: The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases.